Strategy · Operations · Analysis · Markets

The decisions that matter rarely sit inside one discipline. We work where they overlap.

Iota Intel works with founders, executives, investors, and organizations facing consequential decisions – where strategy, operations, markets, regulation, technology, finance, and growth all bear on the same question. The work runs from market assessment and commercialization to financial and scenario analysis, operating strategy, platform and vendor evaluation, partnership development, investor-facing materials, and regulatory intelligence. Unusually deep regulatory capability is part of what we bring, not the whole of it.

16+ years across UnitedHealthcare & Optum Strategy · operations · analytics · market intelligence Entrepreneurial & advisory experience across four continents
§ 01

What we do

Three lanes, one discipline: go to the source, isolate what decides the outcome, and build something a client can act on. Most engagements touch more than one lane, which is usually the reason they land here.

For founders, executives, investors & boards

Strategy, growth & decision support

Consequential growth and operating decisions, worked from the underlying material rather than the summary: market assessment, commercialization, financial and scenario analysis, operating strategy, platform and vendor evaluation, partnership strategy, and investor-facing materials. Current work includes helping a young medical-office real estate platform with strategy, operations, investor communications, platform evaluation, market development, and the practical work of scaling.

For regulated companies, trade associations & coalitions

Regulatory intelligence & public participation

Primary-source analysis of consequential federal, state, and international regulatory developments. We help clients understand what a proposal or requirement actually changes, assess the operational and economic implications, develop a position, prepare sourced public comments, and translate final requirements into an implementation path. Where legal questions arise, our analysis is designed to support discussion with counsel rather than substitute for it.

For organizations entering or expanding into new markets

Markets, partnerships & cross-border strategy

Market entry and commercialization where the commercial, regulatory, and institutional questions cannot be answered separately: pathway and stakeholder mapping, market-access analysis, partnership development, and the procurement, reimbursement, approval, and institutional-adoption considerations that actually gate entry. Experience spans North America, Europe, Asia, and the Gulf. For in-country submissions we team with local specialists; we bring the strategy and the reasoning.

Built for problems that don't fit neatly inside one function.

Iota Intel works directly with decision-makers, moves quickly across disciplines, and brings in additional expertise when the problem calls for it.

§ 02

How we work

Five questions we ask of any consequential decision – an operating choice, a market, an investment, a platform, a partnership, a regulatory change. The discipline is the product, and it does not change with the subject.

01

Frame

What decision is actually being made? What outcome matters here, and which constraints are real rather than assumed?

02

Evidence

What do the data, economics, customers, market signals, source materials, and operating facts actually tell us?

03

Options

What paths are genuinely available, and what are the real tradeoffs rather than the superficial ones?

04

Stress-test

Where could each option fail? Which assumptions carry the answer, and what do counterarguments and independent analyses reveal?

05

Execute

What people, systems, partners, resources, and next steps turn the decision into results?

We don't stop at the abstract level. We examine how a decision lands on the organizations, systems, workers, customers, and investors who actually live with it – which is where most analysis stops short, and where the decisive issues usually are.

On important questions we deliberately run more than one analytical approach, including AI-enabled research agents, to challenge our own assumptions, surface the strongest counterargument, and compare competing readings before we commit to a recommendation. The tools are not the product. Better judgment is.

§ 03

Depth when the details matter

Regulation is where this discipline is easiest to demonstrate, so it is worth showing. Most summaries – news, trade press, even most AI – work from the preamble and give you the gist: that something changed. For an executive that is often enough. For the team that has to implement it, it is not.

01

The text, not the preamble

We work through the operative regulatory text – the binding sections at the back of the rule – one at a time, preserving the agency's own structure while stripping the legalese. The preamble tells you what an agency says it is doing; the text is what actually binds.

02

Implementation-grade

Knowing there is "a new notice requirement" is not enough. You need exactly what it must say, in what font, what must be bold, and every condition that applies – because the rule said so. If you are writing the policy, the process, or the code, you need all of it.

The result is a summary you could read like any other – but one a team can actually build from.

Every iota. The whole picture.

The idea behind the name is granularity without losing the whole. i100 = 1. A complex problem can be sliced into scores of questions, datasets, assumptions, stakeholders, and consequences. The point of going deep is not to produce more fragments. It is to understand every material piece well enough to bring them back together into one coherent view someone can act on.

§ 04

What you receive

Decision-ready work designed to move from analysis to action – whether the next step is entering a market, choosing a platform, strengthening an operating model, preparing an investor conversation, or responding to a regulatory change.

Market & competitive assessments Financial & scenario analyses Operating-model & scaling recommendations Vendor & platform evaluations Commercialization & go-to-market plans Investor & board decision support Market-entry & partnership assessments Fully sourced comment letters & comment strategy Regulatory briefs & final-rule impact reports Implementation & compliance roadmaps
§ 05

Selected filings

Selected public work across healthcare, water, food, consumer safety, technology, and environmental policy. Different questions. Different conclusions. One standard of analysis.
Technical & scientific synthesis

Comment on EPA's Draft Sixth Contaminant Candidate List (CCL 6)

A fully sourced comment on the agency's draft CCL 6 – an evidentiary framework built for durability in the post–Loper Bright environment.

EPA-HQ-OW-2022-0946 · Drinking water · 2026
Request the letter →
Health IT & interoperability

Comment on drug prior authorization & interoperability standards

A comment grounded in global FHIR-adoption evidence and a voluntary industry pledge – pairing U.S. rulemaking with international benchmarking. Filed by founder Bradley Shogren under an Iota Intel affiliation.

CMS-0062-P · Health IT / prior authorization · 2026
Request the letter →
Statutory & APA analysis

Comment on the partial revocation of chlorpyrifos tolerances

A close legal read of a proposed pesticide-tolerance rule – tested against the FFDCA "reasonable certainty of no harm" standard, the agency's duty to respond to significant comments, and the narrowed deference landscape after Loper Bright and Relentless.

EPA-HQ-OPP-2024-0431 · Pesticides / food safety · 2025
Request the letter →
Statutory implementation

Comment on standardized asbestos testing in talc-containing cosmetics

An implementation analysis of a rule executing a specific statutory mandate (MoCRA § 3505) – mapping the testing methodology, phase-in, small-business compliance path, and where the agency's record is strongest.

FDA-2023-N-4225 · Cosmetics / consumer safety · 2025
Request the letter →
Framework & standards design

Comment on a definition and labeling framework for ultra-processed foods

A constructive, build-it-this-way response to an RFI: a workable definition, a tiered disclosure approach, and integration with existing federal data systems – the kind of input an agency can actually operationalize.

FDA-2025-N-1793 · Food & nutrition policy · 2025
Request the letter →
Cost-benefit & deregulatory balancing

Comment on reducing regulatory burdens without reducing safety

Where burden can be cut and where it can't – principles and targeted recommendations balancing compliance cost against measurable risk, with attention to small manufacturers and import certification.

CPSC-2025-0009 · Consumer products · 2025
Request the letter →

Each is part of the public record; full letters are available on request. Every letter is written to be transferable – a model a client can adapt and file under their own name or letterhead.

§ 06

Who we work with

Emerging & middle-market companies Large enterprises & in-house policy teams Healthcare & life-sciences organizations Trade associations & coalitions Investors & boards Organizations entering or expanding in international markets

A founder deciding whether an opportunity is real. An operating team weighing a platform, a market, or a scaling decision. An investor or board that needs the analysis behind a recommendation rather than the recommendation alone. A policy team needing senior surge capacity during a heavy comment period, or arms-length drafting when a position travels better under another name. In every case: focused senior attention, interdisciplinary depth, and a bias toward work that moves from insight into action and execution.

Who's behind Iota Intel

The detail that decides the outcome is rarely the one being discussed.

Iota Intel is led by Bradley Shogren, whose career spans strategy, analytics, operations, market intelligence, regulatory affairs, and international entrepreneurship. He spent more than sixteen years across UnitedHealthcare and Optum, helping leaders in a large matrixed organization separate signal from noise and translate complex issues into operating decisions, most recently while leading a regulatory team. Before UnitedHealth Group he built and ran businesses internationally; since leaving, he has worked alongside founders and operators on markets, commercialization, financial scenarios, platforms, partnerships, and regulation. A former firefighter and first responder, he learned to triage quickly, prioritize under pressure, and act when the consequences are immediate. The combination is the point: strategic judgment, analytical rigor, cross-functional operating experience, and an instinct for turning complexity into action. More about Bradley →

§ 07

Start a conversation

The first step toward solving a complex challenge begins with a conversation.
Email  support@iotaintel.com
Based in  Frisco, Texas
Working  North America · Europe · Asia · the Gulf

Please keep your message general and do not include confidential information. Submitting an inquiry does not create an advisory engagement.

Prefer email? Write us directly at support@iotaintel.com.